BioSpace News Archive

Prevalence of various types of cancers such as breast, prostate, and lung cancer, development of biological & targeted drug therapies, and reliability of cancer biomarkers fuel the growth of the global cancer biomarkers market.

The disposable syringes market was valued $5.45 billion in 2018, and is estimated to generate $8.11 billion by 2026, registering a CAGR of 5.1% from 2019 to 2026.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.

Today, Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray® PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer.

AbbVie (NYSE: ABBV) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ® (upadacitinib, 30 mg, once daily) versus DUPIXENT® (dupilumab, 300 mg, every other week) – both as monotherapy treatments – in adults with moderate to severe atopic dermatitis who were candidates for systemic therapy.

XinThera, a company focused on building a small molecule oncology and immunology pipeline, announced that the company has raised $50M in Series B financing.

Today, the U.S. Food and Drug Administration announced participation in several new collaborative communities aimed at addressing challenges in patient health care.

IMMUNOPRECISE ANTIBODIES LTD. today announces the promotion of Dr. Barry Duplantis, Ph.D., to VP of Client Relations and welcomes Ms. Carla Dahl as VP of Marketing.

Alpine Immune Sciences, Inc. today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2021 after the close of market. Alpine will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT

Zoetis Inc. (NYSE: ZTS) today announced it has entered into an agreement to acquire Jurox, a privately held animal health company, which develops, manufactures and markets a wide range of veterinary medicines for treating companion animals and livestock.